✦ LIBER ✦

Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma : Follow-up at 12 years

✍ Scribed by Emer O. Hanrahan; Kristine Broglio; Deborah Frye; Aman U. Buzdar; Richard L. Theriault; Vicente Valero; Daniel J. Booser; Sonja E. Singletary; Eric A. Strom; James L. Gajewski; Richard E. Champlin; Gabriel N. Hortobagyi

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 163 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21906

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epirubicin-containing high-dose chemothe

Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up

✍ Yoshinori Ito; Taketo Mukaiyama; Makoto Ogawa; Nobuyuki Mizunuma; Shunji Takahas 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 147 KB

P53 is the strongest predictor of surviv

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support

✍ Manfred Hensel; Andreas Schneeweiss; Hans-Peter Sinn; Gerlinde Egerer; Erich Sol 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 129 KB 👁 3 views

## Abstract Our purpose was to determine the predictive value of tumor biologic parameters in patients with HRPBC who received HDCT with ASCT as first‐line treatment. From September 1992 to May 2000, 149 stage II or III HRPBC patients were enrolled in a single‐arm trial using a tandem HDCT regimen

Feasibility and low toxicity of early ra

Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk Stage II–III and locally advanced breast carcinoma

✍ Salomon M. Stemmer; M. Raphael Pfeffer; Shulamith Rizel; Izhar Hardan; Jana Goff 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

Early versus late intensification for pa

Early versus late intensification for patients with high-risk Hodgkin lymphoma—3 Cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation : Five-year results of a randomized trial on behalf of the GOELAMS group

✍ Nina Arakelyan; Christian Berthou; Bernard Desablens; Sophie de Guibert; Vincent 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views